Summary & Overview
HCPCS J2794: Risperidone (Risperdal Consta) Injection, 0.5 mg
HCPCS Level II code J2794 denotes a 0.5 mg unit of risperidone as the long‑acting injectable formulation (Risperdal Consta). Nationally, long‑acting injectable antipsychotics are significant for continuity of care in serious mental illness, affecting medication access, site‑of‑service utilization, and payer coverage policies. This code captures billing for the medication component distinct from administration services.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks on coverage patterns and site‑of‑service use where available, summaries of typical billing practice for medication versus administration line items, and clinical context on the role of long‑acting injectable risperidone in outpatient psychiatric care. The publication highlights payment and coding considerations relevant to facility and professional claims, notes common modifiers used in practice (input provided), and flags areas where input data was not supplied.
This summary is intended to inform coding, billing, and policy stakeholders about how HCPCS Level II code J2794 is applied in ambulatory behavioral‑health settings and how payers typically engage with long‑acting antipsychotic medication billing.
Billing Code Overview
HCPCS Level II code J2794 represents an injection of risperidone (Risperdal Consta), 0.5 mg. This entry describes a single unit of the long‑acting injectable antipsychotic formulation of risperidone.
Service Type: Parenteral medication administration (long‑acting injectable antipsychotic)
Typical Site of Service: Behavioral health clinics, outpatient infusion/clinic settings, psychiatric treatment centers, and other ambulatory care settings where long‑acting injectable antipsychotics are administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or adolescent with schizophrenia, schizoaffective disorder, or other psychotic disorder receiving maintenance long‑acting injectable antipsychotic therapy. The patient presents to an outpatient mental health clinic, community behavioral health center, or psychiatric infusion suite for a scheduled intramuscular administration of risperidone long‑acting injection, billed as J2794 per 0.5 mg increment (Risperdal Consta). Clinical workflow includes medication reconciliation, assessment of recent psychiatric stability and adverse effects, verification of informed consent and vaccination/needle‑site precautions, preparation and reconstitution of the lyophilized risperidone vial (if required), documentation of lot number and expiration, selection of appropriate gauge and needle length, administration into the deltoid or gluteal muscle, observation for immediate reactions (typically 15–30 minutes based on clinic policy), post‑injection site care, and documentation of dose administered and next scheduled injection date. Billing involves the J2794 HCPCS Level II code for the drug product (units reported per 0.5 mg) and any applicable administration or visit codes as appropriate for the setting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered |